---
id: kdigo-glomerulonephritis-2024
title: "KDIGO 2024 Clinical Practice Guideline for the Management of Glomerular Diseases"
short_title: "KDIGO GN 2024"

organization: Kidney Disease Improving Global Outcomes
collaborators: null
country: Global
url: https://kdigo.org/guidelines/
doi: null
pmid: null
open_access: true

specialty: nephrology
guideline_type: clinical-practice
evidence_system: KDIGO GRADE
conditions:
  - glomerulonephritis
  - IgA nephropathy
  - membranous nephropathy
  - lupus nephritis
  - FSGS
tags:
  - immunosuppression
  - proteinuria
  - RAAS blockade
  - rituximab
  - SGLT2 inhibitors

publication_date: 2024-05-01
previous_version_date: 2021-09-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 KDIGO guideline update on the management of glomerular diseases including IgA nephropathy, membranous nephropathy, FSGS, MCD, lupus nephritis, and ANCA-associated glomerulonephritis.

## Key Recommendations

### General Principles
- **Supportive Care (All GN)**: ACEi/ARB to reduce proteinuria, BP control (<130/80), SGLT2 inhibitors (renoprotective), statin if indicated, lifestyle optimization.
- Treat to proteinuria target (<0.5-1 g/day preferred).

### IgA Nephropathy (IgAN)
- **Supportive Care First**: Maximize RAAS blockade for 90 days before considering immunosuppression.
- **SGLT2 Inhibitors**: Recommended.
- **Corticosteroids (Targeted Release Budesonide â€“ Tarpeyo/Nefecon)**: For persistent proteinuria >1 g/day despite supportive care; reduces proteinuria and slows eGFR decline.
- **Systemic Corticosteroids**: Consider for rapidly progressive disease; weigh infection risk.

### Membranous Nephropathy (MN)
- **Anti-PLA2R Antibody Testing**: Positive in ~70% of primary MN.
- **Immunosuppression**: Rituximab (preferred first-line) or cyclophosphamide + corticosteroids for nephrotic syndrome with high risk of progression.
- Monitor anti-PLA2R titers to guide response.

### Minimal Change Disease (MCD)
- **High-Dose Prednisone**: First-line (1 mg/kg/day, max 80 mg). Taper after remission.
- **Calcineurin Inhibitors or Rituximab**: For frequently relapsing or steroid-dependent MCD.

### Focal Segmental Glomerulosclerosis (FSGS)
- Rule out secondary causes (obesity, infections, drugs).
- **Primary FSGS**: Corticosteroids; CNI or rituximab for steroid-resistant cases.

### Lupus Nephritis
- Covered in dedicated LN guidelines (ACR/EULAR); induction with mycophenolate or cyclophosphamide + corticosteroids; maintenance with MMF or AZA; consider voclosporin add-on.
